71 related articles for article (PubMed ID: 28699934)
1. In brief: Avelumab (Bavencio) for metastatic merkel cell carcinoma.
Med Lett Drugs Ther; 2017 Jul; 59(1521):e120. PubMed ID: 28699934
[No Abstract] [Full Text] [Related]
2. Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial.
Lambert J; Marrel A; D'Angelo SP; Burgess MA; Chmielowski B; Fazio N; Gambichler T; Grob JJ; Lebbé C; Robert C; Russell J; Güzel G; Bharmal M
Patient; 2020 Aug; 13(4):457-467. PubMed ID: 32472503
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
Gaiser MR; Bongiorno M; Brownell I
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):345-359. PubMed ID: 29478343
[TBL] [Abstract][Full Text] [Related]
4. Avelumab in the Treatment of Advanced Merkel Cell Carcinoma: A Systematic Review.
Sharma AN; Shah KS; Sharma AA; Yu SS
Dermatol Surg; 2024 May; 50(5):407-411. PubMed ID: 38349855
[TBL] [Abstract][Full Text] [Related]
5. Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts' recommendations.
Munhoz RR; Cayol F; Corrales L; Gerson R; Tilli M; Barreto EO; Sánchez Castillo JO; Schmerling RA; Cinat G
Cancer Immunol Immunother; 2021 Apr; 70(4):1031-1036. PubMed ID: 33104838
[TBL] [Abstract][Full Text] [Related]
6. Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.
D'Angelo SP; Hunger M; Brohl AS; Nghiem P; Bhatia S; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Schlichting M; Hennessy MH; Bharmal M
Cancer Immunol Immunother; 2019 Apr; 68(4):609-618. PubMed ID: 30721341
[TBL] [Abstract][Full Text] [Related]
7. Should adjuvant nivolumab be used in surgically resected Merkel cell carcinoma patients?
Saiag P; Blom A
Lancet; 2023 Sep; 402(10404):751-753. PubMed ID: 37451294
[No Abstract] [Full Text] [Related]
8. Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab.
Shibayama Y; Kameda H; Ota S; Tsuchida K; Cho KY; Nakamura A; Miyoshi H; Atsumi T
J Diabetes Investig; 2019 Sep; 10(5):1385-1387. PubMed ID: 30738003
[TBL] [Abstract][Full Text] [Related]
9. Breaking avelumab resistance with combined ipilimumab and nivolumab in metastatic Merkel cell carcinoma?
Glutsch V; Kneitz H; Goebeler M; Gesierich A; Schilling B
Ann Oncol; 2019 Oct; 30(10):1667-1668. PubMed ID: 31350554
[No Abstract] [Full Text] [Related]
10. Non-Melanoma Skin Cancers: Biological and Clinical Features.
Cives M; Mannavola F; Lospalluti L; Sergi MC; Cazzato G; Filoni E; Cavallo F; Giudice G; Stucci LS; Porta C; Tucci M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751327
[TBL] [Abstract][Full Text] [Related]
11. Metastatic Merkel-cell carcinoma: the dawn of a new era.
O'Brien T; Power DG
BMJ Case Rep; 2018 Jul; 2018():. PubMed ID: 30002209
[TBL] [Abstract][Full Text] [Related]
12. Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences.
Kaufman HL; Dias Barbosa C; Guillemin I; Lambert J; Mahnke L; Bharmal M
Patient; 2018 Aug; 11(4):439-449. PubMed ID: 29512061
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program.
Walker JW; Lebbé C; Grignani G; Nathan P; Dirix L; Fenig E; Ascierto PA; Sandhu S; Munhoz R; Benincasa E; Flaskett S; Reed J; Engelsberg A; Hariharan S; Kasturi V
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32269140
[TBL] [Abstract][Full Text] [Related]
14. Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET/CT-confirmed complete response.
Zijlker LP; Levy S; Wolters W; van Thienen JV; van Akkooi ACJ; Tesselaar MET
Cancer; 2024 Feb; 130(3):433-438. PubMed ID: 37788133
[TBL] [Abstract][Full Text] [Related]
15. Avelumab as an Emerging Therapy for Eyelid and Periocular Merkel Cell Carcinoma.
Garcia GA; Kossler AL
Int Ophthalmol Clin; 2020; 60(2):91-102. PubMed ID: 32205656
[TBL] [Abstract][Full Text] [Related]
16. How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial.
Bharmal M; Guillemin I; Marrel A; Arnould B; Lambert J; Hennessy M; Fofana F
Orphanet J Rare Dis; 2018 Jun; 13(1):95. PubMed ID: 29914528
[TBL] [Abstract][Full Text] [Related]
17. From genetic characterization to new potential therapeutic options: targeting Bcl-xL in Merkel carcinoma.
Kervarrec T
Br J Dermatol; 2023 Jul; 189(1):7. PubMed ID: 37146163
[No Abstract] [Full Text] [Related]
18. Nivolumab-induced sensory ganglionopathy.
Coskun O; Sahin H; Yalcin S; Sahin YC; Coskun U
J Oncol Pharm Pract; 2023 Sep; 29(6):1510-1515. PubMed ID: 37254496
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study.
de Sousa LG; Liu S; Bhosale P; Altan M; Darbonne W; Schulze K; Dervin S; Yun C; Mahvash A; Verma A; Futreal A; Gite S; Cuentas EP; Cho WC; Wistuba I; Yao JC; Woodman SE; Halperin DM; Ferrarotto R
Oral Oncol; 2024 Apr; 151():106747. PubMed ID: 38460288
[No Abstract] [Full Text] [Related]
20. The Effect of Oxaliplatin on the Immunogenic Cell Death and Cell Apoptosis of Human Merkel Cell Cancerous Tumor.
Zhang B
Stud Health Technol Inform; 2023 Nov; 308():437-444. PubMed ID: 38007770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
